Finally, this study also showed that the therapeutic outcome may be improved by RAD52 inactivation of BRCA genes-defective cancers and treated with agents that inhibit PARP, while inducing a minimal toxicity to normal cells. This evidence concerns the gene PARP1 and cancer.